Objectives: Calcinosis Cutis (CaC) represents one of the most frequent and disabling non-lethal manifestations in SSc. Our objectives were to evaluate (1) associations of CaC with SSc clinical characteristics and (2) identify risk factors for CaC development. Methods: EUSTAR database-registered SSc patients with available information on their CaC status were included. We compared baseline patient characteristics (with vs without CaC at baseline) and investigated predictors of CaC development at 5 and 10 years (in those without baseline CaC) with logistic regression analyses. Results: A total of 7114 SSc patients were included. At baseline, 11.9% had CaC. Among 1010 and 997 patients without baseline CaC, 40% and 46% developed CaC within 5 years and 10 years, respectively. Patients with CaC were more frequently female, had longer disease duration, higher modified Rodnan Skin Score, telangiectasia, digital ischaemia, late capillaroscopy patterns, joint contractures, tendon friction rubs, gastrointestinal involvement (all P < 0.001), pulmonary arterial hypertension (PAH) (P = 0.02), joint synovitis, and renal crisis (both P = 0.04). CaC patients had a higher frequency of ACA and anti-PM/Scl antibody positivity (P < 0.001; P = 0.03, respectively). Predictors for the development of CaC at 5 years included longer disease duration [odds ratio (OR) 1.04], cardiac involvement (OR 1.63), late capillaroscopy pattern (OR 1.70), telangiectasia (OR 1.92), digital ulcers (OR 2.60), and PAH (OR 2.10). Predictors at 10 years included longer disease duration (OR 1.03), dcSSc (OR 1.51), female gender (OR 1.85), telangiectasia (OR 1.92), and digital ulcers (OR 2.92). Conclusion: CaC is common and progressive; clinical risk factors may provide insights into the pathogenesis.

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database

Selmi, Carlo Francesco;
2026-01-01

Abstract

Objectives: Calcinosis Cutis (CaC) represents one of the most frequent and disabling non-lethal manifestations in SSc. Our objectives were to evaluate (1) associations of CaC with SSc clinical characteristics and (2) identify risk factors for CaC development. Methods: EUSTAR database-registered SSc patients with available information on their CaC status were included. We compared baseline patient characteristics (with vs without CaC at baseline) and investigated predictors of CaC development at 5 and 10 years (in those without baseline CaC) with logistic regression analyses. Results: A total of 7114 SSc patients were included. At baseline, 11.9% had CaC. Among 1010 and 997 patients without baseline CaC, 40% and 46% developed CaC within 5 years and 10 years, respectively. Patients with CaC were more frequently female, had longer disease duration, higher modified Rodnan Skin Score, telangiectasia, digital ischaemia, late capillaroscopy patterns, joint contractures, tendon friction rubs, gastrointestinal involvement (all P < 0.001), pulmonary arterial hypertension (PAH) (P = 0.02), joint synovitis, and renal crisis (both P = 0.04). CaC patients had a higher frequency of ACA and anti-PM/Scl antibody positivity (P < 0.001; P = 0.03, respectively). Predictors for the development of CaC at 5 years included longer disease duration [odds ratio (OR) 1.04], cardiac involvement (OR 1.63), late capillaroscopy pattern (OR 1.70), telangiectasia (OR 1.92), digital ulcers (OR 2.60), and PAH (OR 2.10). Predictors at 10 years included longer disease duration (OR 1.03), dcSSc (OR 1.51), female gender (OR 1.85), telangiectasia (OR 1.92), and digital ulcers (OR 2.92). Conclusion: CaC is common and progressive; clinical risk factors may provide insights into the pathogenesis.
2026
calcinosis cutis
clinical characteristics
predictor
risk factor
systemic sclerosis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/107167
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact